An interventional study of Drug: Apixaban and Drug: Rivaroxaban in Pulmonary Embolism Acute and Venous Thromboembolism (VTE), sponsored by Combined military hospital lahore. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Combined military hospital lahore · Not applicable, Interventional, and Treatment
Among 37 studies testing apixaban in Venous Thromboembolism — 11 open to participants now, 11 under way, 1 of them phase 3. apixaban · Venous Thromboembolism.
Among the 37 studies testing apixaban in Venous Thromboembolism, this one is the 12th largest by enrollment, is one of 4 that started in 2021, is one of 4 with no phase, and was the 35th registered.
712 studies on the registry are indexed under Venous Thromboembolism; 146 are open to participants now.
This study's enrollment of 540 is above the median of 240 across 401 interventional studies indexed under Venous Thromboembolism.
Browse Venous Thromboembolism studies →11 of the 37 studies testing apixaban in Venous Thromboembolism are open now, in 7 countries. Each count lists the studies.
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →37 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2021.
Median enrollment 100 across the 37 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
3 of 37 have an industry lead sponsor. The 10 most frequent:
Combined military hospital lahore is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Combined military hospital lahore has 1 study filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
7 of the studies testing apixaban in Venous Thromboembolism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
| NCT05683808University of Vermont Medical CenterVenous Thromboembolism Prevention in Outpatients With Glioma | 2026-12-30 |
| NCT07869615Military Hospital of TunisComparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty | 2027-04-15 |
| NCT05735639Imperial College LondonTHRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) | 2027-06-30 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
Among the 37 studies testing apixaban in Venous Thromboembolism, from their registry updates:
This prospective, open-label, randomized controlled trial will compare clinically relevant bleeding during the first three months of treatment with apixaban versus rivaroxaban in adults with acute pulmonary embolism (PE) in a Pakistani cohort. A total of 540 participants will be randomized 1:1 to receive standard acute-treatment regimens of either apixaban or rivaroxaban. The primary outcome will be the composite of major bleeding or clinically relevant non-major (CRNM) bleeding within three months, defined according to International Society on Thrombosis and Haemostasis (ISTH) criteria.
Background: Direct oral anticoagulants (DOACs) are recommended for most eligible patients with acute venous thromboembolism, but comparative bleeding data for apixaban versus rivaroxaban in South Asian populations remain limited. This study will address this knowledge gap by providing direct randomized evidence from a Pakistani cohort.
Study Design: Single-center, prospective, open-label, randomized controlled trial with 1:1 allocation.
Interventions:
Apixaban Group: 10 mg twice daily for 7 days, followed by 5 mg twice daily for the remainder of 3 months
Rivaroxaban Group: 15 mg twice daily for 21 days, followed by 20 mg once daily for the remainder of 3 months
Follow-up Duration: 3 months with monthly assessments
Primary Endpoint: Composite of major bleeding or clinically relevant non-major (CRNM) bleeding within 3 months
Secondary Endpoints: (To be confirmed against protocol)
Major bleeding alone
CRNM bleeding alone
Recurrent venous thromboembolism
All-cause mortality
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 10 mg twice daily for 7 days, then 5 mg twice daily for 3 months total
Drug: Drug: Apixaban
Participants will receive 15 mg twice daily for 21 days, then 20 mg once daily for 3 months total
Drug: Drug: Rivaroxaban
Participants assigned to this arm will receive apixaban administered orally according to the standard acute-treatment regimen for venous thromboembolism
Participants assigned to this arm will receive rivaroxaban administered orally according to the standard acute-treatment regimen for venous thromboembolism.
Composite of major or CRNM bleeding
Number of patients with ISTH-defined major bleeding or clinically relevant non-major bleeding will be assessed
Time frame: 3 months
Major bleeding
Number of patients with ISTH-defined major bleeding will be evaluated
Time frame: 03 months
Plan to share: No — Individual participant data (IPD) will not be shared due to institutional restrictions and ethical considerations. The data will be considered proprietary to Army Cardiac Center, Lahore, Pakistan, and will be subject to institutional data governance policies that prioritize patient confidentiality. The ethics committee approval for this study does not include provisions for sharing de-identified participant data with external researchers. Furthermore, Pakistan's data protection regulations and institutional review board requirements will mandate that all participant-level data remain securely stored within the institution and accessible only to authorized study personnel. Sharing will be further limited because the open-label, single-center design and small number of bleeding events will make the data potentially identifiable even after de-identification. However, aggregated summary statistics, baseline characteristics tables, and fully de-identified outcome data will be made availab
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban
Combined military hospital lahore